Biontech SE
BNTX
查看详细走势图
106.620USD
+1.080+1.02%
收盘 02/06, 16:00（美东）报价延迟15分钟
25.64B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.02%
5天
-6.27%
1月
+8.70%
6月
-4.20%
今年开始到现在
+12.00%
1年
-11.11%
查看详细走势图
TradingKey Biontech SE股票评分
单位: USD 更新时间: 2026-02-06操作建议
Biontech SE当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名52/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价138.01。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Biontech SE评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Biontech SE亮点
亮点风险
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-52.40，处于3年历史低位
机构减仓
最新机构持股54.72M股，环比减少0.02%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值66.49K
分析师目标
根据
22
位分析师
买入
评级
138.005
目标均价
+30.76%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Biontech SE新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Biontech SE简介
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
公司代码BNTX
公司Biontech SE
CEOSahin (Ugur)
网址https://www.biontech.com/
相关品种
